Clinical breast cancer, 2016-02, Vol.16 (1), p.31-37
2016
Details
- Autor(en) / Beteiligte
- Titel
- Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin Combined With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive, Early-Stage Breast Cancer
- Ist Teil von
- Clinical breast cancer, 2016-02, Vol.16 (1), p.31-37
- Ort / Verlag
- United States: Elsevier Inc
- Erscheinungsjahr
- 2016
- Link zum Volltext
- Quelle
- Access via ScienceDirect (Elsevier)
- Beschreibungen/Notizen
- Micro-Abstract Eribulin plus capecitabine as adjuvant therapy was feasible in postmenopausal women with early-stage, human epidermal growth factor receptor 2-negative, estrogen receptor-positive breast cancer. The mean relative dose intensity was 90.6%, and the feasibility rate was 81.3% with the standard dosing schedule for both drugs. An alternative schedule for capecitabine (7 days on, 7 days off) was better tolerated in a supplemental group of 10 patients.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 1526-8209eISSN: 1938-0666DOI: 10.1016/j.clbc.2015.07.007Titel-ID: cdi_proquest_miscellaneous_1753230359
- Format
- –
- Schlagworte
- Adjuvant therapy, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols - therapeutic use, Breast Neoplasms - drug therapy, Capecitabine - administration & dosage, Capecitabine - adverse effects, Chemotherapy, Chemotherapy, Adjuvant - methods, ER-positive, Feasibility Studies, Female, Furans - administration & dosage, Furans - adverse effects, Halaven, Hematology, Oncology and Palliative Medicine, HER2-negative, Humans, Ketones - administration & dosage, Ketones - adverse effects, Middle Aged, Neoplasm Staging, Obstetrics and Gynecology, Postmenopause